Advertisement

ADVERTISEMENT

CLL/MCL

Dr Visco
Videos
Carlo Visco, MD, Discusses Rituximab, Bendamustine, and Cytarabine Plus Venetoclax for MCL
12/15/2021
Carlo Visco, MD, discusses rituximab, bendamustine, and cytarabine followed by venetoclax for high-risk elderly patients with MCL. These data were presented at the 2021 ASH Annual Meeting.
Carlo Visco, MD, discusses rituximab, bendamustine, and cytarabine followed by venetoclax for high-risk elderly patients with MCL. These data were presented at the 2021 ASH Annual Meeting.
Carlo Visco, MD, discusses...
12/15/2021
Oncology
Dr Wang
Videos
Live CLL Cells Inside Bone Marrow Fibroblasts May Have Implication in Drug Resistance
11/29/2021
Lynn Wang, MD, PhD, FCAP, discusses live CLL cells inside the bone marrow fibroblasts and their implication in drug resistance. These data were presented at the 2021 LL&M Congress.
Lynn Wang, MD, PhD, FCAP, discusses live CLL cells inside the bone marrow fibroblasts and their implication in drug resistance. These data were presented at the 2021 LL&M Congress.
Lynn Wang, MD, PhD, FCAP,...
11/29/2021
Oncology
Dr Cheson
Videos
Dr Cheson Discusses Anti-CD20 Monoclonal Antibodies in Patients With CLL
11/23/2021
Bruce Cheson, MD, FACP, FAAAS, FASCO, discusses anti-CD20 monoclonal antibodies for the management of patients with CLL; these data were presented at the virtual LL&M Congress.
Bruce Cheson, MD, FACP, FAAAS, FASCO, discusses anti-CD20 monoclonal antibodies for the management of patients with CLL; these data were presented at the virtual LL&M Congress.
Bruce Cheson, MD, FACP, FAAAS,...
11/23/2021
Oncology
q
Test Your Knowledge
Quiz: BRUIN Study on Pirtobrutinib in Patients With MCL
11/23/2021
True or false: Updated results from the BRUIN study found that pirtobrutinib has promising efficacy in heavily pretreated, poor-prognosis patients with MCL following multiple prior lines of therapy, including a covalent BTK inhibitor.
True or false: Updated results from the BRUIN study found that pirtobrutinib has promising efficacy in heavily pretreated, poor-prognosis patients with MCL following multiple prior lines of therapy, including a covalent BTK inhibitor.
True or false: Updated results...
11/23/2021
Oncology
News
Pirtobrutinib Shows Promising Efficacy in Heavily Pretreated MCL
11/23/2021
Updated results from the BRUIN study found that pirtobrutinib has promising efficacy in heavily pretreated, poor-prognosis patients with MCL following multiple prior lines of therapy, including a covalent BTK inhibitor; these data were...
Updated results from the BRUIN study found that pirtobrutinib has promising efficacy in heavily pretreated, poor-prognosis patients with MCL following multiple prior lines of therapy, including a covalent BTK inhibitor; these data were...
Updated results from the BRUIN...
11/23/2021
Oncology
qqq
Test Your Knowledge
Quiz: Umbralisib Plus Ublituximab for Patients With TN, PT CLL
11/22/2021
True or false: the phase 3 UNITY-CLL study found umbralisib plus ublituximab has a tolerable safety profile and prolonged PFS compared to CIT in patients with both TN and PT CLL.
True or false: the phase 3 UNITY-CLL study found umbralisib plus ublituximab has a tolerable safety profile and prolonged PFS compared to CIT in patients with both TN and PT CLL.
True or false: the phase 3...
11/22/2021
Oncology
News
Umbralisib Plus Ublituximab Yields Longer PFS in Patients With TN, PT CLL
11/22/2021
The phase 3 UNITY-CLL study found umbralisib plus ublituximab has a tolerable safety profile and prolonged PFS compared to CIT in patients with both TN and PT CLL; these data were presented at the 2021 ASH Annual Meeting.
The phase 3 UNITY-CLL study found umbralisib plus ublituximab has a tolerable safety profile and prolonged PFS compared to CIT in patients with both TN and PT CLL; these data were presented at the 2021 ASH Annual Meeting.
The phase 3 UNITY-CLL study...
11/22/2021
Oncology
qqq
Test Your Knowledge
Quiz: Is Orelabrutinib Effective for Patients With R/R CLL/SLL?
11/17/2021
True or false: A phase 2 study confirmed that orelabrutinib is effective for patients with R/R CLL/SLL.
True or false: A phase 2 study confirmed that orelabrutinib is effective for patients with R/R CLL/SLL.
True or false: A phase 2 study...
11/17/2021
Oncology
News
Orelabrutinib Monotherapy Found Effective For Patients With R/R CLL/SLL
11/17/2021
Findings from an updated study have further confirmed that orelabrutinib is effective in patients with R/R CLL/SLL; these data were presented at the 2021 ASH Annual Meeting.
Findings from an updated study have further confirmed that orelabrutinib is effective in patients with R/R CLL/SLL; these data were presented at the 2021 ASH Annual Meeting.
Findings from an updated study...
11/17/2021
Oncology
Dr Lydia Scarfò
Videos
MRD-Driven Therapy With Ibrutinib Plus Venetoclax for R/R CLL
08/12/2021
Lydia Scarfò, MD, discusses an MRD-driven treatment strategy with ibrutinib and venetoclax for R/R CLL. These data were presented at the 2021 EHA Virtual Congress.
Lydia Scarfò, MD, discusses an MRD-driven treatment strategy with ibrutinib and venetoclax for R/R CLL. These data were presented at the 2021 EHA Virtual Congress.
Lydia Scarfò, MD, discusses an...
08/12/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 20 ⁠–⁠ September 22
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use